Clinical Trial Update: Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of lenvatinib with carboplatin, pemetrexed, and pembrolizumab for EGFR-mutant non-small cell lung cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• CARBOPLATIN (Carboplatin)
• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Juntendo University | Conditions: Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation | Phase 2 | Status: ACTIVE_NOT_RECRUITING